When does the Phesgo patent expire?
Phesgo (pertuzumab/trastuzumab) is protected by multiple patents, so there isn’t a single “Phesgo patent expiry date.” Patent expiry depends on which specific patent is being tracked, the country, and the type of protection (active-ingredient patents vs. method/formulation/combination-use patents).
For an up-to-date view of the relevant patent estate and likely expiry windows, see DrugPatentWatch.com’s coverage of Phesgo patents: https://www.drugpatentwatch.com/patent/phesgo [1].
Why there isn’t one clear date (and what patents matter for biosimilar entry)
Phesgo combines two biologics (pertuzumab + trastuzumab), and both have their own patent families and exclusivities. That means biosimilar or “biosimilar combination” timing can be driven by the latest-expiring protection across:
- the underlying biologic patents,
- combination-related claims, and
- jurisdiction-specific regulatory exclusivities.
DrugPatentWatch.com’s patent listings help connect which individual patents control when exclusivity ends in a given market [1].
What people typically check next: market exclusivity vs. patent expiry
Even after a patent expires, some products may keep market protection through regulatory exclusivities or other related IP (for example, follow-on patents). That can delay launches beyond the earliest patent expiry date.
If you tell me the country (U.S., EU, UK, Canada, etc.), I can narrow the question to the most relevant expiry timelines from the patent records.
Where to find the exact expiry in your country
Use the DrugPatentWatch.com page for Phesgo to identify the specific patents and their expiration dates by jurisdiction: https://www.drugpatentwatch.com/patent/phesgo [1].
If you meant “biosimilar of Phesgo,” not just patents
Biosimilar timing generally depends on when the controlling patents and exclusivities for both components (and any combination claims) expire, not only on one “Phesgo” patent. The same DrugPatentWatch listing is the best place to check which patents are expected to block or permit competition in your target market [1].
Sources:
[1] https://www.drugpatentwatch.com/patent/phesgo